RSLS - ReShape Lifesciences Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.83
-0.24 (-11.59%)
At close: 4:00PM EST

1.71 -0.12 (-6.56%)
Pre-Market: 9:13AM EST

Stock chart is not supported by your current browser
Previous Close2.07
Open2.03
Bid1.75 x 1100
Ask1.80 x 1000
Day's Range1.69 - 2.25
52 Week Range1.61 - 3,759.00
Volume1,734,720
Avg. Volume474,304
Market Cap1.091M
Beta (3Y Monthly)2.28
PE Ratio (TTM)N/A
EPS (TTM)-42.38
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.00
Trade prices are not sourced from all markets
  • ACCESSWIRE18 hours ago

    ReShape Lifesciences Announces Third Quarter 2018 Financial Results

    SAN CLEMENTE, CA / ACCESSWIRE / November 14, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial ...

  • ACCESSWIRE23 hours ago

    4 Healthcare Stocks Investors Should Get Familiar With

    CORAL GABLES, FL / ACCESSWIRE / November 14, 2018 / The healthcare sector is the sector of the economy made up of companies that specialize in products and services related to health and medical care. As the industry continues to emerge as a leading place for investors to hedge against broader market volatility, companies like Premier Health Group, Inc. (PHGRF) (PHGI), ReShape Lifesciences Inc. (RSLS), Teladoc (TDOC), and Imprimis Pharmaceuticals, Inc. (IMMY). Premier Health Group, Inc. (PHGRF) (PHGI) is focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry.

  • ACCESSWIRE2 days ago

    Today’s Research Reports on Stocks to Watch: ReShape Lifesciences and ABIOMED

    NEW YORK, NY / ACCESSWIRE / November 13, 2018 / It was a day of red for ReShape Lifesciences and ABIOMED on Monday. Both stocks had double digit losses despite encouraging developments reported. RDI Initiates ...

  • ACCESSWIRE3 days ago

    3 Health Care Stocks Making Moves On Monday; Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Lannett Company, ReShape Lifesciences

    CORAL GABLES, FL / ACCESSWIRE / November 12, 2018 / New trends in Healthcare have helped push biotechnology stocks and healthcare stocks higher this year. Connected health is a new model for healthcare delivery, which provides healthcare services remotely. According to reports* the global connected healthcare market is expected to reach $105,337.5 Million by 2022 at a CAGR of 30.27% during the forecast period.

  • ACCESSWIRE3 days ago

    ReShape Lifesciences Completes Investigator Meeting for ReShape Vest Clinical Trial in the European Union

    SAN CLEMENTE, CA ACCESSWIRE / November 12, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that on November 7, 2018 the company conducted an investigator meeting in conjunction with the trial in the European Union to support CE Marking of the ReShape Vest.TM The investigator meeting took place in Frankfurt, Germany and was intended to further establish relationships with the study team and to prepare investigators for the upcoming clinical trial for the ReShape Vest. Ten bariatric surgeons from The Netherlands, the Czech Republic, Germany and Belgium met with a team from ReShape Lifesciences and the group discussed the ReShape Vest technology and its proper surgical technique for use in addition to reviewing the trial protocol in anticipation of initiating study enrollment.

  • ACCESSWIRE7 days ago

    3 Health Care Stocks Seeing Heightened Activity After Midterms

    Sesen Bio, Inc. (SESN) saw a stronger premarket session on Thursday morning. "2018 has been a year of focused execution for Sesen Bio, led by the advancement of the Phase 3 program for Vicinium for patients with NMIBC," said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio.

  • ACCESSWIRE7 days ago

    ReShape Lifesciences Announces National VA Contract for ReShape Balloon

    SAN CLEMENTE, CA / ACCESSWIRE / November 8, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that ...

  • ACCESSWIRE8 days ago

    ReShape Lifesciences Announces 1-for-140 Reverse Stock Split

    SAN CLEMENTE, CA / ACCESSWIRE / November 7, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that its Board of Directors has declared a 1-for-140 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on November 8, 2018. At that time, each 140 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. As a result of the reverse stock split, proportional adjustments will be made to the number of shares of common stock issuable upon exercise or conversion, and the per share exercise or conversion price, of the company's outstanding warrants, stock options and convertible preferred stock, in each case in accordance with their terms.

  • ACCESSWIRE15 days ago

    ReShape Lifesciences to Host Third Quarter 2018 Conference Call on November 14, 2018

    SAN CLEMENTE, CA / ACCESSWIRE / October 31, 2018 / ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that ...

  • ACCESSWIRE17 days ago

    ReShape Lifesciences Announces Retirement of Series D Preferred Stock

    SAN CLEMENTE, CA / ACCESSWIRE / October 29, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that as of Friday, October 19, 2018, all shares of the Company's Series D Preferred Stock have been converted into ReShape Lifesciences common shares. The Company used the net proceeds from this offering to continue its commercialization efforts, clinical and product development activities, and for other working capital and general corporate purposes. "We are very pleased with the increased financial flexibility the retirement of these shares represent as we continue to set the Company up to finance our working capital requirements, including our upcoming ReShape VestTM trials," stated Dan Gladney, President and Chief Executive Officer.

  • ACCESSWIRE21 days ago

    ReShape Lifesciences Announces Attendance and Presentation at ObesityWeek 2018

    SAN CLEMENTE, CA / ACCESSWIRE / October 25, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that ...

  • ACCESSWIRElast month

    ReShape Lifesciences Announces Investigator Meeting for ReShape Vest Clinical Trial in European Union

    SAN CLEMENTE, CA / ACCESSWIRE / October 8, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that ...

  • ACCESSWIRElast month

    ReShape Lifesciences Presents New Data on Extension of Weight Loss with ReShape Patient Portal

    SAN CLEMENTE, CA / ACCESSWIRE / October 4, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that ...

  • ACCESSWIRE2 months ago

    ReShape Lifesciences Announces Acceptance of Abstract to be Presented at ObesityWeek 2018

    SAN CLEMENTE, CA / ACCESSWIRE / September 24, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that the company has had an abstract accepted by the scientific committee of The Obesity Society. Professor of Medicine, University of Minnesota, during ObesityWeek 2018, an annual meeting co-sponsored by the American Society for Metabolic and Bariatric Surgery (ASMBS) and The Obesity Society (TOS), which is taking place in Nashville, TN on November 15, 2018.

  • ACCESSWIRE2 months ago

    ReShape Lifesciences Announces Poster at IFSO Annual Conference

    SAN CLEMENTE, CA / ACCESSWIRE / September 21, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today ...

  • ACCESSWIRE2 months ago

    ReShape Lifesciences Announces Pricing of Public Offering

    SAN CLEMENTE, CA / ACCESSWIRE / September 18, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced the pricing of its previously announced public offering of 11,688,890 shares of its common stock and warrants to purchase up to 5,844,445 shares of its common stock, at a public offering price of $0.045 per share and associated warrant. The gross proceeds from the offering, before deducting placement agent fees and estimated offering expenses payable by ReShape Lifesciences, are expected to be approximately $0.52 million. All of the securities in the offering are to be sold by ReShape Lifesciences.

  • ACCESSWIRE2 months ago

    ReShape Lifesciences Announces Proposed Public Offering

    SAN CLEMENTE, CA / ACCESSWIRE / September 14, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has commenced a public offering of shares of its common stock and warrants to purchase shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the securities in the proposed offering are to be sold by ReShape Lifesciences.

  • ACCESSWIRE2 months ago

    ReShape Lifesciences Announces New Patent Grant Expanding its Gastric Vest Patent Portfolio

    SAN CLEMENTE, CA / ACCESSWIRE / September 6, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that The State Intellectual Property Office of The People's Republic of China has granted a device patent to the Company that expands the patent portfolio for the ReShape VestTM. ''We are very excited about this patent that helps protect our proprietary, minimally invasive, novel technology to address the significant obesity market in China,'' said Dan Gladney, Chief Executive Officer and Chairman of the Board of ReShape Lifesciences. Research by Imperial College London found that China's obesity rate has skyrocketed in the last 30 years to one of the highest obesity rates in the world.

  • ACCESSWIRE3 months ago

    ReShape Lifesciences to Present at H.C. Wainwright 20th Annual Global Investment Conference

    SAN CLEMENTE, CA / ACCESSWIRE / August 24, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced the ...

  • ACCESSWIRE3 months ago

    ReShape Lifesciences Announces Second Quarter 2018 Financial Results

    SAN CLEMENTE, CA / ACCESSWIRE / August 14, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial ...

  • InvestorPlace3 months ago

    ReShape Lifesciences: Burning Fat Wads of Shareholders’ Cash

    Unfortunately for investors, ReShape Lifesciences (NASDAQ:RSLS) seems much more effective at cash burning than fat burning. The weight loss devices company has fallen on hard times. RSLS stock has plunged more than 90% over the past month and has plummeted more than 99% over the past year.

  • ACCESSWIRE3 months ago

    ReShape Lifesciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / ReShape Lifesciences, Inc. (NASDAQ: RSLS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 4:30 PM Eastern ...

  • ACCESSWIRE3 months ago

    ReShape Lifesciences Announces Termination of Underwriting Agreement for Previously-Announced Public Offering

    SAN CLEMENTE, CA / ACCESSWIRE / August 10, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the underwriting agreement for its underwritten public offering that priced on August 7, 2018 has been terminated by the company's underwriter for the offering in accordance with its terms due to Nasdaq's determination that the offering was not a public offering under the Nasdaq rules, and therefore could not be completed without shareholder approval. As a result of the termination of the underwriting agreement, no shares of common stock will be issued in the underwritten public offering. ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases.

  • ACCESSWIRE3 months ago

    ReShape Lifesciences Announces Pricing of Underwritten Public Offering of Common Stock

    SAN CLEMENTE, CA / ACCESSWIRE / August 7, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 12,514,412 shares of its common stock at a public offering price of $0.085 per share. The offering is expected to close on or about August 10, 2018, subject to the satisfaction of customary closing conditions.The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by ReShape Lifesciences, are expected to be approximately $1.06 million. All of the shares in the offering are to be sold by ReShape Lifesciences.

  • ACCESSWIRE3 months ago

    ReShape Lifesciences Announces Proposed Underwritten Public Offering of Common Stock

    SAN CLEMENTE, CA / ACCESSWIRE / August 7, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the proposed offering are to be sold by ReShape Lifesciences.